After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...